Keratoacanthoma
☆ Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Biasa Keratoacanthoma
References
Keratoacanthoma (KA) mangrupikeun tumor kulit anu sering dikenal kusabab kamekaran gancangna sareng poténsial pikeun mundur sorangan. Ieu ilaharna lumangsung dina heubeul, lalaki kulit adil jeung sajarah karuksakan panonpoé. Nalika panyabutan bedah nganggo eksisi atanapi bedah mikrografi Mohs mangrupikeun perlakuan anu biasa, aya sababaraha pilihan terapi anu sanés.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) mangrupakeun tumor low-grade nu dimimitian dina kelenjar tangtu dina kulit jeung kasampak sarupa squamous cell carcinoma (SCC) dina mikroskop. Masih aya perdebatan ngeunaan naha KA kedah digolongkeun salaku bentuk SCC invasif.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) mangrupikeun jinis kanker anu paling umum kadua di jalma, khususna di antawis sepuh. Bedah biasana dianggo pikeun ngubaran cSCC, tapi pikeun sababaraha pasien anu henteu tiasa dioperasi atanapi milih henteu, pilihan sanés sapertos pangobatan intralesional tiasa dipertimbangkeun. Pangobatan intralesional tradisional (methotrexate or 5-fluorouracil) parantos dianggo, tapi aya panalungtikan anu terus-terusan ngeunaan pendekatan anyar sapertos immunotherapy intralesional sareng virotherapy oncolytic. Di dieu, urang bakal ningali perlakuan intralesional anu béda pikeun cSCC, mimitian ti metode klasik dugi ka strategi canggih.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Dina mikroskop, keratoacanthoma raket pisan nyarupaan karsinoma sél skuamosa. Nalika sababaraha ahli patologi mengklasifikasikan keratoacanthoma salaku éntitas anu béda sareng sanés ganas, sakitar 6% tina keratoacanthoma klinis sareng histologis ngalakukeun kamajuan kana kanker sél skuamosa invasif sareng agrésif.
○ Diagnosis sareng Perawatan
#Dermoscopy
#Skin biopsy